USSTOCK.TODAY
Market Closed
Log in Sign up

Traws Pharma Inc(TRAW) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

TRAW
TRAW
Traws Pharma Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$0.23
-0.01 ▼ -5.15%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$0.23
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -2.31Insider Own ⓘ 29.34%Shs Outstand ⓘ 15.3MPerf Week ⓘ -19.24%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 10.9MPerf Month ⓘ -38.83%
Enterprise Value ⓘ -0.00BPEG ⓘ -EPS next Q ⓘ -0.11Inst Own ⓘ 25.53%Short Float ⓘ 6.3%Perf Quarter ⓘ -56.6%
Income ⓘ -0.02BP/S ⓘ -EPS this Y ⓘ -223.17%Inst Trans ⓘ 12.36%Short Ratio ⓘ 1.14Perf Half Y ⓘ -84.56%
Sales ⓘ 0.00BP/B ⓘ 2.08EPS next 5Y ⓘ -ROA ⓘ -159.21%Short Interest ⓘ 0.68MPerf YTD ⓘ -79.65%
Book/sh ⓘ 0.11P/C ⓘ 0.7EPS past 3/5Y ⓘ -ROE ⓘ -433.36%52W High ⓘ -92.88% ($3.23)Perf Year ⓘ -89.1%
Cash/sh ⓘ 0.33P/FCF ⓘ -Sales past 3/5Y ⓘ 131.12% 64.59%ROIC ⓘ -1275.34%52W Low ⓘ 5.17% ($0.22)Perf 3Y ⓘ -98.59%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 83.59%Gross Margin ⓘ -Volatility(W/M) ⓘ 17.34% 14.13%Perf 5Y ⓘ -99.71%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -100%Oper. Margin ⓘ -ATR (14) ⓘ 0.04Perf 10Y ⓘ -100%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 0.93EPS Q/Q ⓘ -22.55%Profit Margin ⓘ -RSI (14) ⓘ 34.32Recom ⓘ 3
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 0.93Sales Q/Q ⓘ -100%SMA20 ⓘ -16.91% ($0.28)Beta ⓘ 1.68Target Price ⓘ $1
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ 2026/11/16SMA50 ⓘ -43.05% ($0.4)Rel Volume ⓘ 0.14Prev Close ⓘ $0.24
Employees ⓘ 7LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ 12.2% -SMA200 ⓘ -77.54% ($1.02)Avg Volume(3M) ⓘ 0.60MPrice ⓘ $0.23
IPO ⓘ 2013/7/25Option/Short ⓘ No/YesTrades ⓘ 330Volume ⓘ 87,137Change ⓘ -5.15%
Company
TRAW TRAWTraws Pharma Inc | NASD | Biotechnology Deep dive

This is a small U.S. clinical-stage biotech listed on Nasdaq whose main pipeline consists of oral antivirals designed to target respiratory viruses such as avian influenza (H5N1), seasonal flu, and COVID-19. Its lead candidates are TXM, a single-dose, cap-dependent endonuclease inhibitor, and lutetrelvir, a ritonavir-free 3CL protease inhibitor.

Quote

Over the past 1 year, on the lower side

93% below its 1-year high.

Now $0.23
52w low$0.2252w high$3.23
52W Range0%
Volume ⓘ 87,137

Traded less than usual. That is 14% of its average volume.

D
Overall · many cautions
We judged 6 of the 8 questions below. 3 need caution.
No data for valuation, dividends, or not applicable.
ETFs holding this stock 2 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #554 of 598 in the industry

Based on market cap of $4M.

FAQ

FAQ

What kind of company is TRAW?

TRAW belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of TRAW?

The market cap of TRAW is approximately $4M, ranking 5,647 within its sector.

What is the 52-week high and low for TRAW?

TRAW has recorded a 52-week high of $3.23 and a low of $0.22.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels